CircFOXM1 was a crucial promotor of sorafenib resistance in HCC that can interact with miR-1324 to stimulate MECP2 expression and therefore strengthened sorafenib resistance in HCC (67). This evidence concerns the gene MECP2 and hepatocellular carcinoma.